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PCASE3
IMPACT OF DRUG POLICY ON IMPROVING ACCESS TO MEDICINES  
IN DELHI
Bapna J1, Bhoi N2
1Indian Institute of Health Management Research, Jaipur, India, 2Ministry of Health & Family 
Welfare (MOH&FW), New Delhi, Delhi, India
ORGANIZATION: Indian Institute of Health Management Research (IIHMR), 
Jaipur, India & Delhi Society for Promotion of Rational Use of Drugs (DSPRUD), 
Delhi PROBLEM OR ISSUE ADDRESSED: In 1994, when efforts for developing a 
drug policy were made, the availability and use of medicines in Delhi government 
hospitals was poor. Most of the prescribed drugs expected to be given free of cost to 
patients were not available at the hospital pharmacy. Unneeded medicines such as 
drug combinations, herbal medicines, and tonics were stocked in the stores. At this 
time the Delhi Society for Promotion of Rational Use of Drugs (DSPRUD), a Non-
Governmental Organization (NGO) consisting of government and non-government 
members, was formed to improve the situation. This group assisted the government 
in framing the drug policy and its implementation through support from WHO. 
GOALS: To assess the impact of the drug policy in Delhi in terms of availability of 
essential medicines, change in stockout days, and expenditure on essential and non 
essential drugs. OUTCOMES ITEMS USED IN THE DECISION: The quantity of 
drugs procured from the Essential Drugs List (EDL) and outside the EDL; money spent 
on these; changes in stockout days for the key drugs; and change in utilization patterns 
of health services by patients. IMPLEMENTATION STRATEGY: Implementation of 
elements of the drug policy such as selection of essential drugs and an improved 
procurement system for medicines. Design: Retrospective data were collected through 
record reviews. The data for two years before (1993–1994, 1994–1995) and two years 
after (2000–2001, 2001–2002) the drug policy were assessed. Setting and Population: 
Two public sector hospitals at Delhi that serve a large section of the population, one 
with 1350 beds (large) and the other with 550 beds (medium), were selected by the 
convenient purposive sampling method. RESULTS: After the implementation of the 
drug policy, the availability of drugs increased by 25% in the large and 98% in the 
medium hospital. The drugs procured from the EDL increased from 62% to 78% in 
the large and 74% to 87% in the medium hospital. Of the total expenditure, the 
money spent on essential drugs increased from 73% to 85% in the large and 87% to 
93% in the medium hospital, whereas money spent on nonessential drugs decreased 
from 27% to 15% in the large and 13% to 7% in the medium hospital. The average 
number of stockout days for key dugs decreased from 33 to 16 days in the large and 
from 143 days to 33 days in the medium hospital. The utilization pattern of health 
services by patients increased by 8% in the large and by 35% in the medium hospital. 
LESSONS LEARNED: The implementation of the drug policy in the state of Delhi 
has led to increased availability of essential drugs. This type of intervention can serve 
as a model for improving access to medicines by implementing an effective drug policy 
through an NGO working with the government,and involving bureaucratic and politi-
cal commitment.
PCASE4
HOW TO IMPLEMENT NATIONAL ESSENTIAL MEDICINE LIST IN 
SHANGHAI: PROS & CONS
Hu S, Zhang YB, He J
Health Development and Research Center, Shanghai Bureau of Health, Shanghai, China
ORGANIZATION: Shanghai is a municipal in China where has 14 million residents 
and 6 million migrated populations. The Bureau of Health is the health authority and 
has the jurisdiction of health legislation and policy implementation in Shanghai. 
PROBLEM OR ISSUE ADDRESSED: The study is to identify how to implement 
national essential medicine policy in an economic advanced municipality. GOALS: 
From the perspectives of policy makers, it needs not only to follow the central 
government requirements but also to adopt the local situation OUTCOMES ITEMS 
USED IN THE DECISION: Progress indicators used in monitoring and evaluation of 
essential medicine policy IMPLEMENTATION STRATEGY: The situation analysis 
is needed. Information of availability and affordability of essential medicines should 
be evaluated by WHO/HAI method in Shanghai. The distribution of essential 
medicines in different level of hospitals is analysed from bulk purchasing data base 
and IMS data CHPA. The pharmaceutical expenditure in 2001–2007 will be collected 
from Shanghai sub-national health accounts. RESULTS: Shanghai is an important 
pharmaceutical market in China. The total pharmaceutical expenditure was 17.5 
billion Yuan (RMB) in Shanghai in 2007. The share of pharmaceutical expenditure 
in total health expenditure was 30.6%, which was equal to 1.47% GDP. Eighty 
percent of pharmaceuticals were sold from hospital channel, among them, 67% of 
cost spent in outpatient department and 32%, in inpatient department. The ratio 
between western (chemical) medicines and traditional Chinese medicines was 84% 
and 16%, respectively. The mark-up ratio used to be 20%-30%, which are main 
component in hospital revenue. Since 2009, China has conducted a nationwide 
health system reform. By the time of 2011, China will establish a preliminary national 
essential medicine system, 307 items of medicines have been selected by central 
government as a national essential medicines list and will used in all urban community 
centres and rural township health centres. The selection of essential medicines is based 
on the principle of opinion leaders, evidence medicine and pharmacoeconomic 
evaluation. China has launching an initiative on medical and pharmaceutical 
system reform since April, 2009 after publishing government ofﬁcial documents. 
According to the survey, as a matter of fact, the medicines used in urban community 
centres in Shanghai have already accounted for nearly 2000 items. Only did 25% 
value or volume of pharmaceuticals are belonged to 307 essential medicines. 
How to adjust the utilization of essential medicines is the challenge facing to the policy 
makers. LESSONS LEARNED: It is really a trade-off. Universal coverage of essential 
medicine is a human right. The implementation of national essential medicine policy 
will offer safety, effective, convenience and affordable medicines to release the 
economic burden of the patients. However, if the primary hospital only allows using 
national essential medicines, it will let the patient ﬂown to the secondary or tertiary 
hospital. The role of gatekeeper will diminish in the primary health care. This case 
will tell you that the decision made by Shanghai municipal government are as follows: 
(1) Under the framework of national essential medicine list, Shanghai will adjust the 
number and forms of essential medicines to meet the need of 85% pharmaceutical 
pattern in the primary health care; (2) All grass-root health facilities will allocate 
and use essential medicines; (3) Zero mark-up ratio will be used in the sale of 
medicines in primary hospital, meantime, adjustment of reimbursement system is 
necessary, including increasing government ﬁnancial support and reforming the fee 
schedule in hospital; (4) drug bulk purchasing and distribution through market 
competition and public bidding system; (5) rational use of drug and diagnostic 
procedure guided by clinical pathway; (6) Strengthening the monitoring and evaluation 
of essential medicine policy. The WHO country progress indicators will be used in 
Shanghai.
PCASE5
DEVELOPMENT OF A COOPERATIVE PHYSICIAN-PHARMACIST 
MEDICATION THERAPY MANAGEMENT MODEL FOR THE 
POLYPHARMACY ELDERLY IN TAIWAN
Lin HW1, Yu IW2, Chang CK2, Yao SH2, Lai ZR2, Tsai HH1, Liu CS2, Lin CC1
1China Medical University, Taichung, Taiwan, 2China Medical University Hospital, 
Taichung, Taiwan
ORGANIZATION: China Medical University hospital (CMUH), a 2000-bed medical 
center, in Taiwan. PROBLEM OR ISSUE ADDRESSED: Upon the National Health 
Insurance coverage, the rapid growth of health care utilization in Taiwan raises the 
concerns about the potentials for waste and misadventure. Given managing polyphar-
macy can be an overwhelming task, it is crucial to develop a suitable integrated care 
model in medical settings to facilitate appropriate medication use in the elderly. 
GOALS: The goals were 1)to establish a cooperative physician-pharmacist medication 
therapy management (PP-MTM) model for the polypharmacy elderly in CMUH and 
2)to assess its economic, clinical and humanistic outcomes. OUTCOMES ITEMS 
USED IN THE DECISION: The assessment outcomes included patients’ health care 
utilization, medication adherence, EQ-5D, occurrence of adverse drug reactions, basic 
activity of daily living and satisfaction. IMPLEMENTATION STRATEGY: A ran-
domized, controlled intervention study was designed. Patients with the following 
characteristics were included: greater than 65 years old, frequent and loyal outpatient 
users in CMUH, with multiple chronic illnesses, and polypharmacy. While patients in 
the PP-MTM group receive intensive, continuous MTM care and assessments, those 
patients in the usual care group receive only follow-up assessments for one year. The 
project was approved by IRB in CMU and fully sponsored by the Department of 
Health in Taiwan. RESULTS: The professional focus group in the PP-MTM model, 
consisting of geriatricians and well-trained clinical pharmacists, were formed and 
discussed about medication-related issues on a regular basis. By January 13, 2010, 36 
elderly patients in both groups were recruited. Up to 120 patients for each group are 
expected. LESSONS LEARNED: Currently, the major barrier was to bridge the com-
munications between specialty physicians and professionals in CMUH and with other 
settings. The patient-centered outcomes were not exactly outweighed the professional 
self-esteem in current practice environments so that further communications and 
discussions are needed.
PCASE6
THE FINANCIAL IMPACT OF A DAILY AVERAGE CONSUMPTION 
(DACON) ANALYSIS IN A US PHARMACY BENEFIT MANAGEMENT 
(PBM) COMPANY
Rice G1, Carlton R2, Regan T2
1MedImpact Health Systems Inc., San Diego, CA, USA, 2Xcenda, Palm Harbor, FL, USA
Parts of this research were sponsored by and conducted in collaboration with Cepha-
lon, Inc. ORGANIZATION: MedImpact is a Pharmacy Beneﬁt Management (PBM) 
company serving more than 32 million members nationwide. PROBLEM OR ISSUE 
ADDRESSED: There is a need in the managed care setting to rigorously compare 
pharmaceuticals with similar therapeutic indications for formulary coverage decisions 
based on clinical advantages, utilization, and budgetary differences. Modaﬁnil and 
armodaﬁnil are indicated to improve wakefulness in patients with treated obstructive 
sleep apnea, shift work disorder and narcolepsy. While both medications are approved 
for once-daily dosing with different multiple tablet strengths, there are utilization 
differences between the products. Addressing these utilization differences surrounding 
the commercial availability of a new therapy with less than six months of claims data 
becomes even more challenging. GOALS: (1) To examine the real-world utilization of 
armodaﬁnil and modaﬁnil based on DACON. (2) To apply economic modeling tech-
niques in the DACON analysis to determine the pharmacy budget impact of 
armodaﬁnil and modaﬁnil. OUTCOMES ITEMS USED IN THE DECISION: The 
primary measure used in the analysis was DACON from pharmacy claims data applied 
to economic modeling. The analysis was not speciﬁc to dosage regimen or indication. 
IMPLEMENTATION STRATEGY: The DACON of armodaﬁnil and modaﬁnil were 
examined in a large retrospective database analysis of Wolters Kluwer Source LX 
pharmacy analytic ﬁle between March 2009 and October 2009. The study dates were 
chosen to provide 5 full months of armodaﬁnil claims data after commercial avail-
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ability (June 1, 2009) and 3 months of data prior to account for patients who switched 
from modaﬁnil to armodaﬁnil. DACON was calculated by dividing the total tablets 
dispensed by the total days supplied. MedImpact subsequently conducted a DACON 
analysis using its pharmacy claims data from 3rd quarter of 2009. The MedImpact 
DACON values for armodaﬁnil and modaﬁnil were examined and incorporated into 
economic modeling of the pharmacy budget impact. The cost per day of therapy was 
calculated as the weighted average cost per tablet (based on wholesale acquisition cost 
as of January 2010), exclusive of any discounts or rebates multiplied by the MedIm-
pact DACON. RESULTS: DACON results for armodaﬁnil was 1.03 based on 21,085 
armodaﬁnil prescriptions and the DACON for modaﬁnil was 1.40 based on 278,985 
modaﬁnil prescriptions in the Wolters Kluwer Source LX data. In the MedImpact 
analysis, DACON values for armodaﬁnil was 1.05 and the DACON for modaﬁnil 
was 1.47. The DACON for armodaﬁnil and modaﬁnil was applied to an economic 
model using a simulated 1,000,000 member life plan of which 0.5% of the lives were 
treated with modaﬁnil. In the period prior to commercial availability of armodaﬁnil, 
the utilization was 100% modaﬁnil. Based on economic modeling using the MedIm-
pact DACON and difference in the daily cost of both therapies, based on 7% actual 
utilization of armodaﬁnil, the projected cost savings was $469,755. On a per-member 
per month (PMPM) basis this simulated population experienced a cost savings of 
$0.039 PMPM. A 25% utilization of armodaﬁnil would provide a projected cost 
savings of $1,677,696 and a PMPM savings of $0.140 PMPM. LESSONS LEARNED: 
In this simulated population, the data suggests that armodaﬁnil with a lower DACON 
and cost per tablet compared to modaﬁnil would save $469,755 over 1 year in this 
therapeutic class. MedImpact consistently examines the utilization of pharmaceuticals 
with similar indications by analyzing DACON and other metrics using retrospective 
claims analysis in tandem with budget impact models. DACON provides real-world 
utilization that can have a signiﬁcant impact on pharmacy budgets. Private payers 
should leverage their access to claims data that can help to more accurately measure 
pharmaceutical utilization. By using pharmaceutical claims data in tandem with well-
designed economic models, payers can better estimate current and future spending.
